Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours

NCT06022692 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Tumor

Interventions

DEVICE: Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
DRUG: tislelizumab (BeiGene, China) combined with PD-1 inhibitor

Sponsor

Pengyuan Liu

Collaborators

[object Object]